Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II chemoradiotherapy plus consolidation CAPOX for lower rectal cancer
jRCTs021190023Phase 2Recruiting
- Start
- Apr 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of capecitabine and oxaliplatin in rectal adenocarcinoma and rectal cancer. Primary endpoint: clinical complete response rate. Started Apr 2020; status: recruiting.
02
Drugs
capecitabineoxaliplatin
03
Conditions
rectal adenocarcinomarectal cancer
Beyond the preview
Go deeper on jRCTs021190023.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs021190023.